Akt/NF-κB/MAPK-IN-1 

Akt/NF-κB/MAPK-IN-1 (compound 2m) is a potent and orally active inhibitor against NO (IC₅₀=7.70 μM) with no significant toxicity. Akt/NF-κB/MAPK-IN-1 shows anti-inflammatory activity by inhibiting Akt/NF-κB and MAPK signaling pathways^[1].

Akt/NF-κB/MAPK-IN-1 (compound 2m) (0-20 μM, 24 h) significantly decreases the levels of TNF-α, IL-1β, IL-6 and PGE2, down-regulates the expression of iNOS and COX-2 in LPS (10 ng/mL)-induced RAW264.7 cells^[1].
Akt/NF-κB/MAPK-IN-1 (0-20 μM, 24 h) can block LPS-induced phosphorylation of p38, ERK and JNK in RAW264.7 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Akt/NF-κB/MAPK-IN-1 (compound 2m) (10-20 mg/kg, IG, for 7 consecutive days) reduces LPS-induced inflammatory disease in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

604.86

C₃₈H₅₆N₂O₄

O[C@@H]1[C@@]2([H])[C@@]3([H])[C@@]([C@@](CC3)([H])[C@H](C)CCC(N4CCN(CC4)C(/C=C/C5=CC=C(C=C5)C)=O)=O)(CC[C@]2([H])[C@@]6([C@](C[C@@H](CC6)O)([H])C1)C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Li X, et al. Design, synthesis and evaluation of ursodeoxycholic acid-cinnamic acid hybrids as potential anti-inflammatory agents by inhibiting Akt/NF-κB and MAPK signaling pathways. Eur J Med Chem. 2023 Aug 31;260:115785.  [Content Brief]